Displaying 241 - 260 of 462
FTC Seeks Public Input in Review of the Recycled Oil Rule
Moonlight Slumber, In the Matter of
FTC Challenges Proposed Merger of Major Titanium Dioxide Companies
FTC Proposes Updates to R-Value Rule for Home Insulation Products
FTC Staff Issues FY 2015 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors
Rust-Oleum Corporation (Painter’s Touch 2X Ultra Cover spray paint)
Mayfair Industries Inc. (Garcinia Cambogia ZT/Garcinia Cambogia Allure dietary supplement)
Moonlight Slumber, LLC; Analysis to Aid Public Comment; Proposed Consent Agreement
Illinois Firm Barred from Making Misleading Baby Mattress Claims
Baxter International Inc., Claris Lifesciences Limited, and Arjun Handa, In the Matter of
Baxter International Inc. and Claris Lifesciences Limited have agreed to divest two types of pharmaceutical products to settle charges that Baxter’s proposed $625 million acquisition of Claris’ injectable drugs business would (1) reduce current competition in the United States for the antifungal agent fluconazole in saline intravenous bags, which is used to treat fungal and yeast infections, and (2)reduce future competition in the U.S. market for intravenous milrinone, which dilates the blood vessels, lowers blood pressure and allows blood to flow more easily through the cardiovascular system. Under the FTC order, the parties will divest all of Claris’s rights to fluconazole in saline intravenous bags and milrinone in dextrose intravenous bags to New Jersey-based pharmaceutical company Renaissance Lakewood LLC. The order requires Baxter to supply Renaissance with fluconazole in saline intravenous bags and milrinone in dextrose intravenous bags for up to five years while transferring the manufacturing technology to Renaissance or its contract manufacturing designee. Baxter is also required to assist Renaissance in establishing its manufacturing capabilities and securing the necessary FDA approvals.
Federal Trade Commission Closes Investigation of Honeywell International, Inc. and E.I. DuPont de Nemours & Co.
Honeywell International, Inc./E.I. du Pont de Nemours & Co.
FTC Approves Final Order with Sherwin-Williams and Valspar, Preserving Competition in the North American Market for Industrial Wood Coatings
Sherwin-Williams/Valspar, In the Matter of
The Sherwin-Williams Company agreed to settle charges that its proposed $11.3 billion acquisition of Valspar Corporation is likely anticompetitive by selling Valspar’s North America Industrial Wood Coatings Business to Axalta Coating Systems Ltd. The transaction would combine Sherwin-Williams and Valspar, two of the top three industrial wood coatings manufacturers. According to the complaint, the acquisition as originally proposed likely would reduce competition in the North American market for industrial wood coatings used to make furniture, kitchen cabinets, and building products. Under the terms of the consent agreement, Sherwin-Williams will divest to Axalta two Valspar industrial wood coatings plants, one in High Point, North Carolina, and the other in Cornwall, Ontario. Axalta will also receive the research and development facilities, warehouses and testing facilities of Valspar’s Industrial Wood Coatings Business, as well as customer contracts, intellectual property, inventory, accounts receivable, government licenses and permits, and business records.
Prepared Statement of the Federal Trade Commission on "Antitrust Concerns and the FDA Approval Process,” Before the Subcommittee on Regulatory Reform, Commercial and Antitrust Law of the Judiciary Committee, United States House of Representatives
FTC Testifies before House Judiciary Committee’s Subcommittee on Regulatory Reform, Commercial and Antitrust Law about Antitrust Concerns and the FDA Approval Process
Displaying 241 - 260 of 462